Clinical Trials Logo
  1. Home
  2. Cutaneous T-Cell Lymphoma
  3. NCT06285370

A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

Cutaneous T-Cell Lymphoma Clinical Trial

Official title:
An Open-Label, Multicenter, Single Arm Study to Evaluate the Efficacy and Safety of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

Clinical Trial Summary

The purpose of the study is to evaluate the efficacy and safety of mogamulizumab (KW-0761) in chinese subjects with mycosis fungoides or sézary syndrome previously treated with systemic therapy

Clinical Trial Description

This is an open-label, multicenter, single arm study. This study consists of three parts: the Pretreatment Period, the Treatment Period, and the Follow-up Period. Subjects who meet all of eligibility criteria by the screening examination will be enrolled into the study, and start treatment with mogamulizumab within 30 days after obtaining consent. Mogamulizumab will be administered at the dose of 1.0 mg/kg as an intravenous (iv) infusion over at least 1 hour on Days 1, 8, 15, and 22 of Cycle 1 and on Days 1 and 15 of subsequent cycles. Each treatment cycle is set as 28 days. Subjects will continue the treatment of mogamulizumab until any of the criteria for study withdrawal is met. After stopping treatment, the end-of treatment examination will be conducted within 30 days after the last dose.The primary efficacy analysis will be conducted once all subjects terminate treatment by the confirmation of PD/drug intolerance/unacceptable toxicity or 12 months after the date of the first mogamulizumab administration of the last subject of entire study, whichever comes first. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06285370
Study type Interventional
Source Kyowa Kirin Co., Ltd.
Contact Jie Qian
Phone +86 18516142266
Email jie.qian.m5@kyowakirin.com
Status Recruiting
Phase Phase 4
Start date May 29, 2023
Completion date January 31, 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT00038025 - A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies Phase 2
Not yet recruiting NCT02881749 - Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides Phase 2
Completed NCT00744991 - A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma Phase 2
Completed NCT00099593 - Immunization Against Tumor Cells in Sezary Syndrome Phase 2
Completed NCT02593045 - Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) Phase 1
Recruiting NCT00779896 - Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study Phase 1/Phase 2
Recruiting NCT00177268 - Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Completed NCT01728805 - Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Phase 3
Withdrawn NCT00969085 - Trial of Curcumin in Cutaneous T-cell Lymphoma Patients Phase 2
Completed NCT00412997 - LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma Phase 1
Completed NCT00254332 - Effect of Denileukin Diftitox on Immune System in CTCL Patients N/A
Recruiting NCT04296786 - Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study Phase 2
Completed NCT00071084 - Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin. Phase 2
Completed NCT00896493 - Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Phase 2
Terminated NCT00699296 - Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma Phase 2
Completed NCT02676778 - Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma Phase 2
Terminated NCT02061449 - Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma Phase 1
Completed NCT01134341 - Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma Phase 1
Recruiting NCT05296304 - A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides Phase 1